Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the presentation of pre-clinical data at the annual meeting of the American Association for Cancer Research demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed, and establish immune memory to eliminate secondary tumors.

The presentation is entitled “A modified FcγRI expressing T cell (SolidT) exhibits profound anti-tumor activity followed by maturation into effector memory t cells that can be reactivated to kill a secondary tumor.” It will be presented as part of the Adoptive Cell Therapies 4 Session, Poster Section 1, between 1:30 and 5:00 PT on Tuesday, April 9.

Until now, treatment of solid tumors with autologous T-cell therapies, such as CAR-T, have been limited by T-cell exhaustion, toxicity, and immunosuppressive tumor microenvironments. Furthermore, each solid tumor target requires a unique CAR-T cell product. Gilboa’s SolidT technology overcomes these limitations by utilizing a novel, engineered antibody receptor whereby the SolidT cells are activated specifically against high antigen expressing tumor cells, while sparing normal cells with low expression of the same antigens. The SolidT cells are engineered to target tumor cells via coadministration with therapeutic monoclonal antibodies. This activation mechanism prevents premature exhaustion, while also reducing the risk of systemic cytokine-related toxicities. It also allows for a single manufacturing process to generate SolidT cells to be used across multiple tumor types.

The abstract can be viewed here.

The poster can be viewed here.